Introduction: Boussignac CPAP has recently been considered as an alternative to mechanical ventilation for AHRF after open cardiac surgery. Objectives: The study aims to: 1) Evaluate the effectiveness of Boussignac CPAP on clinical profile and arterial blood gases in treating AHFR after cardiac surgery. 2) Identify the success rate and adverse effects of Boussignac CPAP. Subjects and method: Controlled clinical trial included 35 patients with AHRF after open cardiac surgery. Patients were treated by Boussignac APCP. Measurements of MAP, HR, RR, PaO2, PaO2/FiO2 and PaCO2 before and after procedure were compared. Duration, success rate and disadvantages of Boussignac CPAP were noted. Results: MAP, HR, RR measurements were stabilised gradually. ABGs just before, at 30, 60 minutes after and at the end of procedure revealed as following: PaO2 increased from 71.6 to 148.3 to 155.8 to 166.1mmHg; PaO2/FiO2 increased from 208.3 to 297.4 to 311.8 to 332.9mmHg. PaCO2 decreased from 52.7 to 38.6 to 37.1 to 35.3mmHg (p<0.001). The duration of Boussignac CPAP ranged from 2.09+/-0.5 to 51.2+/-14.1h, dependent on AHRF causes. The success rate was 97.1% with minor adverse effects. Conclusion: Boussignac CPAP can be considered as a safe procedure with high success rate. It can improve significantly MAP, HR, RR, oxygenation (PaO2, PaO2/FiO2) and ventilation (PaCO2). The duration of Boussignac CPAP in patients with hemodynamic-originated AHRF was significantly shorter than that in patients with nonhemodynamic-originated AHRF.
Boussignac CPAP: AHRF ; Cardiac surgery